[EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND CHRONIC METABOLIC DISEASES [FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET MÉTABOLIQUES CHRONIQUES
摘要:
公开号:
WO2014087323A3
作为产物:
描述:
alkaline earth salt of/the/ methylsulfuric acid 在
palladium on activated charcoal 、 乙醇 作用下,
生成 O1-acetyl-D-mannitol
Starch plasticized, wholly or in part, with isosorbide, isomannide, isoidide, or a mixture thereof is disclosed. Blends of the plasticized starch and a synthetic polymer, like a polyolefin, also are disclosed.
Process for the preparation of polymeric biosurfactants
申请人:COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
公开号:US10106627B2
公开(公告)日:2018-10-23
The present invention relates to polymeric biosurfactants isolated from two bacterial strains of Microbacterium sp. strain BS-2 [MTCC 5822] and Brevibacillus sp. strain BS-207 [MTCC 5823]. The present invention relates to an acidic exopolysaccharide (EPS), termed Microsan, with chemical composition of glucose, mannose and glucuronic acid (β-D-glucuronyl-(1-2)-D-mannosyl-(1-4)-D-glucose) produced by Microbacterium sp. strain BS-2 and a neutral EPS, termed Brevisan, of galactomannan with galactose and mannose residues in the ratio of 1:1 produced by Brevibacillus sp. strain BS-207. Both these polysaccharides exhibited surface-active and potential antibacterial, antioxidant, anti-inflammatory, and immunomodulatory activities.
Thermoplastic starch composition derivatives from agricultural byproducts
申请人:TEXCHEM POLYMERS SDN BHD
公开号:US10196490B2
公开(公告)日:2019-02-05
A thermoplastic starch composition acquired from compounding a mixture comprises starch-containing agricultural waste in 45 to 70% by weight of total composition that the agricultural waste contains starch content less than 50% in dry weight; thermoplastic synthetic polymer in 25 to 50% by weight of total composition; plasticizer in 1 to 10% by weight of total composition; and coupling agent in 1 to 5% by weight of total composition; wherein the compounding is performed at a first temperature which is higher than room temperature.
Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
申请人:RK Pharma Solutions LLC
公开号:US11332495B2
公开(公告)日:2022-05-17
Methods for preparing degarelix acetate are provided that include the steps of providing a suitable resin; deprotecting the resin with a diethylenetriamine solution; reacting sequentially the deprotected resin with different Fmoc protected amino acids; deprotecting the amino acid in each sequence with a diethylenetriamine solution in a stepwise fashion to yield a degarelix crude compound; and purifying the degarelix crude compound to yield pharmaceutically acceptable degarelix acetate. Methods of preparing degarelix acetate-mannitol premix and the resulting degarelix acetate-mannitol premix are also provided.
A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.